Novo Nordisk's Dual Narrative: Promising Hemophilia Data and Steady Buybacks vs. a Glitch in the Obesity Pipeline

Novo Nordisk shares gain 1.29% to €43.32, buoyed by aggressive share repurchases and clinical data, but obesity pipeline setbacks and rising Eli Lilly competition temper the rally.

Novo Nordisk ended the week at €43.32, notching a 1.29% gain in Friday’s session. The move capped a 30-day stretch that has delivered nearly 17% in returns, powered by a mix of clinical wins, aggressive share repurchases, and cautious analyst optimism. Yet the picture is more nuanced beneath the surface, with a pipeline hiccup in obesity and intensifying competition from Eli Lilly tempering the rally.

The backbone of the recent uptrend remains the company’s buyback programme. Since February 4, 2026, Novo has repurchased 23,009,179 B?shares at an average price of 270.32 Danish kroner apiece, equating to more than €830 million in total spending. The current tranche, launched on May 6 under EU safe?harbour rules, targets additional purchases of up to 11.2 billion kroner through February 1, 2027. The programme — capped at 15 billion kroner over twelve months — has provided a structural floor for the stock, which had plunged to a March low of €30.25 before beginning its recovery. At current levels, shares have climbed more than 43% from that trough and now trade above both the 50?day moving average (€39.51) and the 200?day moving average (€40.60). The 14?day RSI stands at 66, suggesting elevated but not yet extreme momentum.

On the research front, the week brought two contrasting signals. At the International Society on Thrombosis and Haemostasis congress in Paris, Novo presented long?term data from the phase 3 extension study FRONTIER4 for Denecimig (Mim8), its subcutaneous prophylaxis candidate for haemophilia A. The results, covering dosing intervals of once monthly, every two weeks, and once weekly, were described by company executives as confirming the drug’s potential irrespective of inhibitor status — a positive read?through for a pipeline that had faced some scepticism earlier in the year.

Less encouraging was the withdrawal of a phase 2 study for CagriSema, the company’s next?generation combination candidate for type 2 diabetes and obesity. The trial, filed on July 7, had been designed to compare two different injection systems — a device?focused question rather than a pure efficacy test. While analysts viewed the move as manageable and unlikely to affect near?term sales, it raises questions about the device strategy for future combination therapies and hands a potential window to rivals, particularly in the fast?moving obesity space.

On the commercial side, Novo Nordisk rolled out its weekly basal insulin Awiqli in India this week, cutting the annual injection burden from 365 to 52 for people with diabetes. India, already the seventh country to launch the product, has roughly six million patients on insulin, a figure the company expects to grow to nine million in the near future. The expansion comes as competition from Eli Lilly intensifies in key markets: in South Korea, Mounjaro generated around 323.2 billion won in first?quarter sales, more than triple that of Wegovy. Novo responded by cutting Wegovy’s wholesale price by roughly 40% and merging its obesity and diabetes units in the country — a defensive consolidation that underscores the pressure in the GLP?1 arena.

Analysts are taking a measured view. HSBC lifted its price target last week to 300 Danish kroner from 280, while maintaining a “Hold” rating. Danske Bank went further, setting a target of 365 kroner with a “Buy” recommendation. The next major catalyst will come with the second?quarter earnings report, which will test whether the recent rally reflects genuine fundamental improvement or is merely a technical bounce driven by buyback demand and short?covering. Until then, Novo Nordisk remains caught between the steady support of its share repurchase machine and the lingering uncertainties surrounding its next?wave obesity pipeline.